Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neurocognitive Effects of Extended-Release Methylphenidate in Healthy Adults
NCT07742631Phase 1Completed
- Sponsor
- University of the Witwatersrand
- Start
- Feb 2023
- Primary completion
- Apr 2024
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of methylphenidate hydrochloride extended-release chewable tablet (2 arms), sponsored by University of the Witwatersrand. Primary endpoint: Peak Oxygen Consumption at 14 days. Started Feb 2023; status: completed.
02
Drugs
methylphenidate hydrochloride extended-release chewable tablet
Beyond the preview
Go deeper on NCT07742631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07742631.